Pharvaris Closes $132.3M Public Offering, Including Full Over-Allotment Exercise

summarizeSummary

Pharvaris N.V. has successfully closed its underwritten public offering, raising approximately $132.3 million in gross proceeds, which includes the full exercise of the over-allotment option.

check_boxKey Events

• Offering Closed

  Pharvaris N.V. completed its underwritten public offering on May 11, 2026, following the underwriting agreement dated May 8, 2026.

• Substantial Capital Raised

  The company raised approximately $132.3 million in gross proceeds by selling 4,455,863 ordinary shares at a public offering price of $29.68 per share. Net proceeds are expected to be approximately $124 million.

• Full Over-Allotment Exercise

  The underwriters fully exercised their option to purchase an additional 581,199 ordinary shares, indicating strong demand for the offering.

• Funding for Clinical Programs and Commercialization

  Proceeds will primarily fund research and development expenses for late-stage clinical programs, expand the U.S. sales and marketing team, and cover general corporate purposes.

auto_awesomeAnalysis

This filing confirms the successful closing of a substantial public offering, including the full exercise of the underwriters' over-allotment option, which increased the total capital raised to approximately $132.3 million. This significant funding provides crucial runway for Pharvaris's late-stage clinical programs and commercialization efforts, especially following recent positive clinical data. The strong demand, evidenced by the full over-allotment exercise, indicates investor confidence in the company's prospects despite the dilutive nature of the offering.